1. Mahvi DA, Liu R, Grinstaff MW, Colson YL, Raut CP. Local cancer recurrence: the realities, challenges, and opportunities for new therapies. CA Cancer J Clin. 2018;68(6):488-505.

2. Shah V, Bhaliya1 J, Patel GM. In silico docking and ADME study of deketene curcumin derivatives

3. (DKC) as an aromatase inhibitor or antagonist to the estrogen‑alpha positive receptor (Erα+): potent application of breast cancer. Struct Chem. 2022;33(2):571-600.

4. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424.

5. Adhikari N, Baidya SK, Jha T. Effective anti-aromatase therapy to battle against estrogen-mediated breast cancer: comparative SAR/QSAR assessment on steroidal aromatase inhibitors. Eur J Med Chem. 2020;208:112845.

6. Grizzi G, Ghidini M, Botticelli A, Tomasello G, Ghidini A, Grossi F, Fusco N, Cabiddu M, Savio T, Petrelli F. Strategies for increasing the effectiveness of aromatase inhibitors in locally advanced breast cancer: an evidence-based review on current options. Cancer Manag Res. 2020;12:675.

7. Santen RJ, Simpson E. History of estrogen: its purification, structure, synthesis, biologic actions, and clinical implications. Endocrinology. 2019;160(3):605-25.

8. Korzets Y, Yariv O, Mutai R, Moore A, Shochat T, Goldvaser H. The Impact of Endogenous Estrogen Exposures on the Characteristics and Outcomes of Estrogen Receptor Positive, Early-stage Breast Cancer. Discov Oncol. 2021;12(1):26.

9. Starek-Świechowicz B, Budziszewska B, Starek A. Endogenous estrogens-breast cancer and chemoprevention. Pharmacol Rep. 2021;73(6):1497-512.

10. Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer lett. 2015;356(2):231-43.

11. Jha T, Adhikari N, Halder AK, Saha A. Ligand-and structure-based drug design of non-steroidal aromatase inhibitors (NSAIs) in breast cancer. Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment. IGI Global, 2015: 400-70.

12. Hero M, Varimo T, Raivio T. Aromatase inhibitors in puberty. Curr Opin Endocr Metab Res. 2020;14:37-41.

13. Patel HK, Bihani T. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 2018;186:1-24.

14. Rani S, Raheja K, Luxami V, Paul K. A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors. Bioorg Chem. 2021;113:105017.

15. Kümler I, Knoop AS, Jessing CA, Ejlertsen B, Nielsen DL. Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant. ESMO open. 2016;1(4):e000062.

16. Ghosh D, Lo J, Egbuta C. Recent progress in the discovery of next generation inhibitors of aromatase from the structure-function perspective. J Med Chem. 2016;59(11):5131-48.

17. Akça KT, Demirel MA, Süntar I. The Role of Aromatase Enzyme in Hormone Related Diseases and Plant-Based Aromatase Inhibitors as Therapeutic Regimens. Curr Top Med Chem. 2022;22(3):229-46.

18. Karkola S, Wähälä K. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: a molecular modelling study. Mol Cell Endocrinol. 2009;301(1-2):235-44.

19. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015;14(2):111-29.

20. Romano JD, Tatonetti NP. Informatics and computational methods in natural product drug discovery: a review and perspectives. Front. genet. 2019;10:368.

21. Pohl F, Kong Thoo Lin P. The potential use of plant natural products and plant extracts with antioxidant properties for the prevention/treatment of neurodegenerative diseases: in vitro, in vivo and clinical trials. Molecules. 2018;23(12):3283.

22. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770-803.

23. Rupasinghe H. Special Issue "flavonoids and their disease prevention and treatment potential": Recent advances and future perspectives. Molecules. 2020;25(20):4746.

24. Cao Y-L, Lin J-H, Hammes H-P, Zhang C. Flavonoids in Treatment of Chronic Kidney Disease. Molecules. 2022;27(7):2365.

25. Lephart ED. Modulation of aromatase by phytoestrogens. Enzyme Res. 2015;2015.

26. Davis JM, Murphy EA, Carmichael MD. Effects of the dietary flavonoid quercetin upon performance and health. Curr Sports Med Rep. 2009;8(4):206-13.

27. Awasthi M, Singh S, Pandey VP, Dwivedi UN. Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer. J Biomol Struct Dyn. 2015;33(4):804-19.

28. Praseetha NG, Divya UK, Nair S. Identifying the potential role of curcumin analogues as anti-breast cancer agents; an in silico approach. Egypt J Med Hum Genet. 2022;23(1):100.

29. Ali A, Jan NU, Ali S, Ahmad B, Ali A, Samrana S, Jahan A, Ali H, Khan IA, Rahim H, Ali I. Steroidal alkaloids efficient aromatase inhibitors with potential for the treatment of postmenopausal breast cancer. Chem Biol Drug Des. 2020;95(2):233-9.

30. Gürbüz P, Doğan ŞD, Gündüz MG, Uzun K, Uzunhisarcıklı E, Yerer MB. Isolation, Characterization and in Silico Studies of Secondary Metabolites from Jurinea macrocephala DC. with Antiproliferative Activity. Chem Biodivers. 2022;19(4):e202100867.

31. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009;457:219-23.

32. (a) Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235-49.

33. (b) Shah V, Bhaliya J, Patel GM. In silico docking and ADME study of deketene curcumin derivatives (DKC) as an aromatase inhibitor or antagonist to the estrogen-alpha positive receptor (Erα+): potent application of breast cancer. Struct Chem. 2022;33(2):571-600.

34. Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43(21):3867-77.

35. (a) Goel RK, Singh D, Lagunin A, Poroikov V. PASS-assisted exploration of new therapeutic potential of natural products. Med Chem Res. 2011;20:1509-14.

36. (b) Muegge I, Heald SL, Brittelli D. Simple selection criteria for drug-like chemical matter. J Med Chem. 2001;44(12):1841-6.

37. Banjare L, Verma SK, Jain AK, Thareja S. Design and pharmacophoric identification of flavonoid scaffold‐based aromatase inhibitors. J Heterocycl Chem. 2020;57(9):3483-92.

38. Rampogu S, Park C, Son M, Baek A, Zeb A, Lee G, Lee KW. Modulation of aromatase by natural compounds-A pharmacophore guided molecular modelling simulations. S Afr J Bot. 2019;120:230-40.

39. El-Kersh DM, Ezzat SM, Salama MM, Mahrous EA, Attia YM, Ahmed MS, Elmazar, MM. Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer. Sci Rep. 2021;11(1):7121.

40. Rafeeq MM, Sain ZM, Alturki NA, Alzamami A, Asiri SA, Mashraqi MM, Alqosaibi AI, Alnamshan MM, Almutairi A, Alanazi AM, Alam Q. Computational Screening of Natural Compounds for the Discovery of Potential Aromatase Inhibitors: A Promising Therapy for Estrogen-Dependent Breast Cancer. J Pharm Res Int. 2021;33:72-8.

41. Hamed AN, Abouelela ME, El Zowalaty AE, Badr MM, Abdelkader MS. Chemical constituents from Carica papaya Linn. leaves as potential cytotoxic, EGFR wt and aromatase (CYP19A) inhibitors; a study supported by molecular docking. RSC advances. 2022;12(15):9154-62.

42. Rampogu S, Park C, Ravinder D, Son M, Baek A, Zeb A, et al. Pharmacotherapeutics and molecular mechanism of phytochemicals in alleviating hormone-responsive breast cancer. Oxid Med Cell Longev. 2019;2019.

43. Ma WL, Chang N, Yu Y, Su YT, Chen GY, Cheng WC, et al. Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. Cancer Med. 2022;11(14): 2824-35.